Alternative tools allowed the US Food and Drug Administration to avoid a substantial number of prior approval inspections during the coronavirus pandemic, potentially helping cement their use in the post-COVID-19 world.
Sau Lee, deputy director of science in the FDA Center for Drug Evaluation and Research’s Office of Pharmaceutical Quality, said...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?